How to Choose a Centre for Immunotherapy — What to Check Before You Commit

Not the infusion. Almost any day-care unit can give it safely on the day. What matters is whether the centre can recognise and treat an immune-related side effect fast — a named oncologist who owns your case, an after-hours number that reaches a clinician, same-day bloods, steroids and a bed without delay, and specialists to escalate to.

Families comparing centres tend to compare the visible things: the waiting area, the day-care chairs, the distance from home, the number on the estimate. None of those is the thing that decides how immunotherapy goes. Checkpoint inhibitors do not make people unwell in the chair the way chemotherapy often does. They occasionally make people unwell weeks later, at home, in ways that look like an ordinary stomach upset or an ordinary cough until they are not. The centre you choose is really the answer to one question: if that happens on a Sunday night, who picks up, and what do they do in the first hour?

For accuracy about our own service line: at CION, immunotherapy is administered as day care — you come in, are treated, and go home the same day. Response-assessment PET-CT is coordinated at partner imaging centres, not owned by CION, and those scans are billed by the imaging centre directly. CION does not provide CAR-T or cell therapy. Ask every centre you approach to be equally specific about what it does itself and what it sends out.

Eight, asked in the same words at every centre so the answers can be laid side by side. Put them to the treating team and the desk, and ask for written answers. A centre that cannot describe what it does when a side effect starts at night has answered the most important one already.

1. 1

   “Who is my treating oncologist, and will the same doctor see me at every cycle?”

   Immunotherapy is a continuity decision more than a procedure. A slow-developing side effect is far easier to spot when one doctor has seen the whole timeline.

2. 2

   “What number do I call at 2am, and who answers it?”

   Ask for the number now, not on the first cycle day. Ask what happens if the first number does not answer, and write the second one down too.

3. 3

   “If I develop loose motions or breathlessness, what happens in the first hour?”

   You want a described sequence — come in, bloods, review, steroids if indicated. A promise to call you back the next working day is not a sequence.

4. 4

   “Do you admit your own immunotherapy patients, or transfer them?”

   Both answers can be acceptable. Only one of them is acceptable without a named receiving hospital and a stated way of getting there.

5. 5

   “Which specialists can you reach, and how fast?”

   Gastroenterology, pulmonology, cardiology and endocrinology are the four that matter most here. Ask for the realistic timeline, not the theoretical one.

6. 6

   “What is monitored before every cycle, and what periodically?”

   Ask who reads the results, what triggers a call back to you, and how you receive a copy of every report for your own file.

7. 7

   “Where is response imaging done, and who raises that bill?”

   Where imaging is coordinated at a partner centre, that bill comes from the imaging centre and will never appear on the hospital estimate.

8. 8

   “Can I have an itemised, dated written estimate before the first cycle?”

   Medicine and dose per cycle, cycle count, day care, monitoring bloods, imaging, and what treating a side effect would add. A verbal figure is not an estimate.

Asking two or three centres the same eight questions is normal and expected, and it changes nothing about the care you receive at any of them. If you want these written out in a form you can carry from desk to desk, see Questions to Ask a Centre Before Starting Immunotherapy.

More than most families expect, and all of it before the first cycle. The oncologist’s qualification and registration. That the medicine is dispensed on the bill by the hospital pharmacy. The scheme and insurance position, dated. An itemised estimate. And which organisation raises which bill.

• The treating oncologist’s qualification and registration. DM or DNB in medical oncology is the relevant training for prescribing checkpoint inhibitors and managing what follows. Registration with a state medical council is a matter of public record; you may simply ask the centre for the registration number and check it.
• That the medicine is dispensed by the hospital pharmacy and appears on the bill. Counterfeit checkpoint inhibitors have been reported entering the Indian market ahead of patent expiry. A cold-chain medicine bought off-bill cannot be traced, verified or returned. Ask to see the product, the batch number and the invoice, and decline any arrangement that routes the drug outside the hospital pharmacy.
• The scheme empanelment and insurance position, in writing and dated. Empanelment, package contents and ceilings change. Ask the hospital’s scheme desk and your own insurer separately, and get each position dated. No hospital can commit an insurer or a scheme on your behalf, and a reassurance across a counter is not a coverage decision.
• An itemised, dated written estimate. Indicative, as of the date it carries. The lines that matter are the medicine and dose per cycle, how many cycles the figure covers, day-care administration, pre-cycle bloods, hormone monitoring, imaging, review consultations and what an immune side effect would add as an outpatient and as an admission.
• Who raises which bill. Where response-assessment imaging is coordinated at a partner imaging centre rather than done in-house, that organisation bills you directly and the amount will not appear on the hospital’s estimate at all. Ask which bills come from where before you compare any two totals.
• That a second opinion is welcome. A centre confident in its plan will not object to your taking the reports elsewhere, and will hand you copies of the pathology, the biomarker report and the imaging without friction. Reluctance to release your own records is itself an answer.

None of this is a comparison between named hospitals, and this page does not rank centres. It is a method for interrogating whichever centres are in front of you — including ours. Ask us the same eight questions, and hold our answers to the same standard.

No. Size is a proxy, not the criterion. What matters is whether the specific capabilities above exist and are reachable day and night. A smaller unit with a named oncologist, same-day bloods, steroids on the shelf and a written escalation route to a named hospital can be a reasonable place to be treated.

The reverse is also true, and worth saying plainly: a large hospital where nobody with authority is reachable after 6pm is not made safe by being large. The capability list is the test, and it can be applied to a centre of any size. Run through it item by item, and let the answers rather than the building decide.

Where size does begin to matter is at the far end of the risk curve. Severe immune myocarditis, severe pneumonitis and adrenal crisis are uncommon, but when they occur they need intensive care, specialist input within hours, and a team that has seen the picture before. That is a genuine argument for either being treated somewhere with that backup, or agreeing in advance and in writing exactly where you would be moved and how. The wrong version of this conversation is the one that happens for the first time in an ambulance. This is worked through in more detail in Can a Small Local Centre Give Immunotherapy Safely?

Far enough to reach real capability, close enough to get back quickly when something goes wrong. Families plan the journey to the cycles and forget the unplanned journey. Cycles are typically every two to six weeks; a side effect can bring you back on any day in between. Travel times are indicative.

• Count the return journeys, not just the cycles. A centre four hours away is entirely manageable for a planned infusion and very difficult at 2am with breathlessness. Both journeys are part of the treatment, and only one of them appears on the schedule.
• Agree the local fallback in advance. If distance is unavoidable, decide before the first cycle which nearby hospital you would go to first in an emergency, and make sure your treating team knows and has agreed the plan.
• Carry the paperwork that makes you treatable elsewhere. A one-page treatment summary naming the drug, the dose, the dates of cycles and the treating oncologist’s contact turns a confusing 2am presentation into a manageable one. Keep it on paper and on the phone.
• Cost the travel honestly. Fares, an attendant’s time off work and lodging on cycle days are real amounts over a course lasting many months, and they are the amounts that quietly derail treatment. Put them in the family budget alongside the medical estimate.
• Ask whether some visits can be local. Whether any part of monitoring can be done nearer home, with the reports sent to the treating oncologist, is a reasonable question. It is a clinical decision, not an administrative one, so ask the oncologist rather than assuming.
• Do not let distance alone push you to a centre that fails the capability list. The shorter journey is only better if the destination can do the job. Where the two conflict, the conversation belongs with your oncologist, with both trade-offs stated out loud.

CION operates 35+ centres across Telangana and Andhra Pradesh, which for many families changes the arithmetic of how far treatment and follow-up have to be from home. Travel times are indicative and depend on where you start. For district families weighing this up, see Travelling From the District for Immunotherapy and Government vs Private Immunotherapy Access in Telangana.

CAR-T and other cell therapies are not the same thing as checkpoint-inhibitor immunotherapy, and they are delivered by a small number of accredited centres in India. CION does not provide CAR-T or cell therapy and does not stock CAR-T products. If it is being considered for you, the correct step is a referral.

The practical difference is the machinery around the treatment. A checkpoint inhibitor is an antibody given as a day-care infusion. CAR-T involves collecting a patient’s own immune cells, having them modified in a manufacturing facility, and giving them back under inpatient monitoring, because the reactions that can follow — including cytokine release syndrome and neurological effects — need to be managed on site and at speed. That is why accreditation, not enthusiasm, decides which centres can offer it.

Our role here is orientation and onward referral: explaining what is involved, what questions to ask an accredited centre, and helping you get your records there in a usable form. Nothing on this page should be read as CION administering, stocking or arranging CAR-T product. If a centre presents cell therapy to you as routinely available, ask which accreditation it holds and ask to see it.

Take the capability list to the centres in front of you and get the answers written down. These companion pages give you the script to ask with, the honest position on smaller units, and how the government and private routes differ in Telangana before you commit to either.

• Questions to Ask a Centre Before Starting Immunotherapy — the full question list in a form you can carry from desk to desk, with what a good answer sounds like.
• Can a Small Local Centre Give Immunotherapy Safely? — where size genuinely matters, where it does not, and what a smaller unit must have in place first.
• Government vs Private Immunotherapy Access in Telangana — how the two routes differ on waiting, scheme cover and monitoring, so distance and cost can be weighed together.
• Immunotherapy at CION Cancer Clinics — how eligibility review, day-care treatment, monitoring between cycles and cost counselling fit together as one pathway.

The Questions Are Yours to Ask

Asking two or three centres the same eight questions is normal, expected, and changes nothing about the care you receive.